GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mabpharm Ltd (HKSE:02181) » Definitions » EBITDA Margin %

Mabpharm (HKSE:02181) EBITDA Margin % : -165.20% (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Mabpharm EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Mabpharm's EBITDA for the six months ended in Dec. 2023 was HK$-77.95 Mil. Mabpharm's Revenue for the six months ended in Dec. 2023 was HK$47.19 Mil. Therefore, Mabpharm's EBITDA margin for the quarter that ended in Dec. 2023 was -165.20%.


Mabpharm EBITDA Margin % Historical Data

The historical data trend for Mabpharm's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mabpharm EBITDA Margin % Chart

Mabpharm Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial - - -296.16 -271.97 -159.57

Mabpharm Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7,349.48 -305.62 -236.12 -154.05 -165.20

Competitive Comparison of Mabpharm's EBITDA Margin %

For the Biotechnology subindustry, Mabpharm's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mabpharm's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mabpharm's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Mabpharm's EBITDA Margin % falls into.



Mabpharm EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Mabpharm's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-152.126/95.335
=-159.57 %

Mabpharm's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-77.954/47.187
=-165.20 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mabpharm  (HKSE:02181) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Mabpharm EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Mabpharm's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Mabpharm (HKSE:02181) Business Description

Traded in Other Exchanges
N/A
Address
Lujia Road East, Koutai Road West, Block G79, China Medical City, Taizhou, CHN, 225300
Mabpharm Ltd is a biopharmaceutical company. The company is engaged in the research, development, and production of new drugs and biosimilars for cancers and autoimmune diseases. Its core products include CMAB008 (infliximab), CMAB007 (omalizumab), and CMAB009 (cetuximab).
Executives
Guo Jianjun 2307 Founder of a discretionary trust who can infl
Asia Mabtech Limited
Asia Pacific Immunotech Venture Limited
Guo Family (ptc) Limited
Fortune-healthy Investment Limited
Link Best Capital Limited
Cdh Fund V, L.p.
Cdh Mabtech Limited
Cdh V Holdings Company Limited
China Diamond Holdings Company Limited
China Diamond Holdings V Limited

Mabpharm (HKSE:02181) Headlines

No Headlines